Medication info
Nuborjet Tablet 80/2.5/10/10 Milligrams

Nuborjet Tablet 80/2.5/10/10 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium Micronized›10.4mg / 1 tabletS-Amlodipine Besylate Dihydrate›3.69mg / 1 tabletEzetimibe›10mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500656 · Approved 2025.03.21 · Insurance code 643309650

Summary

Main use
Treatment of dyslipidemia (hypercholesterolemia, etc.) and essential hypertension
Who takes it
Adults
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/S-amlodipine (amlodipine) combination and the rosuvastatin/ezetimibe combination. The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Swallow this medicine whole without chewing, dividing, or crushing it. ○ Telmisartan/S-amlodipine (amlodipine) The recommended dose of the telmisartan/S-amlodipine (amlodipine) combination is once daily. It is recommended that the dose be adjusted using the individual components (telmisartan or S-amlodipine [amlodipine]) before administering the telmisartan/S-amlodipine (amlodipine) combination. However, if blood pressure is not controlled with the individual components as follows, switching directly to the telmisartan/S-amlodipine (amlodipine) combination may be considered. - 40/2.5 milligrams: Administer to patients whose blood pressure is not adequately controlled with S-amlodipine 2.5 milligrams (amlodipine 5 milligrams) or telmisartan 40 milligrams. - 80/2.5 milligrams: Administer to patients whose blood pressure is not adequately controlled with S-amlodipine 2.5 milligrams (amlodipine 5 milligrams). - 40/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with telmisartan 40 milligrams or 80 milligrams. - 80/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with telmisartan 80 milligrams or this medicine 40/5 milligrams. ◦ Patients with hepatic impairment: The daily dose of telmisartan in patients with mild or moderate hepatic impairment should not exceed 40 milligrams. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, start treatment at a low dose and increase the dose gradually. ○ Rosuvastatin/ezetimibe Patients receiving the rosuvastatin/ezetimibe combination, whether before or during treatment, must continue a standard cholesterol-lowering diet. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment target, and response. Primary hypercholesterolemia The dose range of the rosuvastatin/ezetimibe combination is 5/10mg to 20/10mg once daily. The recommended initial dose is 5/10mg once daily. For patients requiring a greater reduction in LDL cholesterol, the dose may be adjusted. After starting the rosuvastatin/ezetimibe combination or adjusting the dose, check blood lipid levels at intervals of at least 4 weeks and adjust the dose accordingly; the dose may be increased to a maximum of 20/10mg once daily. Patients taking the telmisartan/S-amlodipine (amlodipine) combination together with the rosuvastatin/ezetimibe combination may switch to this medicine (a combination containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia (hypercholesterolemia, etc.) and essential hypertension

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • elevated total cholesterol
  • elevated LDL-cholesterol
  • elevated Apo B protein
  • elevated triglycerides
  • elevated non-HDL-cholesterol
View approved original text

This medication is used for patients who need to manage both hypertension and dyslipidemia simultaneously. It is particularly helpful for patients with essential hypertension whose blood pressure is insufficiently controlled even while taking a combination of telmisartan and S-amlodipine (amlodipine). It is also used as an additional treatment option for patients using a combination of rosuvastatin and ezetimibe who need to control conditions such as hypercholesterolemia or mixed dyslipidemia. This medication helps stabilize blood pressure, lower bad cholesterol and triglyceride levels, and increase good cholesterol levels. Therefore, it is used to effectively improve both hypertension and dyslipidemia.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/S-amlodipine (amlodipine) combination and the rosuvastatin/ezetimibe combination. The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Swallow this medicine whole without chewing, dividing, or crushing it. ○ Telmisartan/S-amlodipine (amlodipine) The recommended dose of the telmisartan/S-amlodipine (amlodipine) combination is once daily. It is recommended that the dose be adjusted using the individual components (telmisartan or S-amlodipine [amlodipine]) before administering the telmisartan/S-amlodipine (amlodipine) combination. However, if blood pressure is not controlled with the individual components as follows, switching directly to the telmisartan/S-amlodipine (amlodipine) combination may be considered. - 40/2.5 milligrams: Administer to patients whose blood pressure is not adequately controlled with S-amlodipine 2.5 milligrams (amlodipine 5 milligrams) or telmisartan 40 milligrams. - 80/2.5 milligrams: Administer to patients whose blood pressure is not adequately controlled with S-amlodipine 2.5 milligrams (amlodipine 5 milligrams). - 40/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with telmisartan 40 milligrams or 80 milligrams. - 80/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with telmisartan 80 milligrams or this medicine 40/5 milligrams. ◦ Patients with hepatic impairment: The daily dose of telmisartan in patients with mild or moderate hepatic impairment should not exceed 40 milligrams. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, start treatment at a low dose and increase the dose gradually. ○ Rosuvastatin/ezetimibe Patients receiving the rosuvastatin/ezetimibe combination, whether before or during treatment, must continue a standard cholesterol-lowering diet. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment target, and response. Primary hypercholesterolemia The dose range of the rosuvastatin/ezetimibe combination is 5/10mg to 20/10mg once daily. The recommended initial dose is 5/10mg once daily. For patients requiring a greater reduction in LDL cholesterol, the dose may be adjusted. After starting the rosuvastatin/ezetimibe combination or adjusting the dose, check blood lipid levels at intervals of at least 4 weeks and adjust the dose accordingly; the dose may be increased to a maximum of 20/10mg once daily. Patients taking the telmisartan/S-amlodipine (amlodipine) combination together with the rosuvastatin/ezetimibe combination may switch to this medicine (a combination containing the same amounts of each active ingredient) for convenience.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters. If pregnant, use should be discontinued immediately. If symptoms like muscle pain or weakness occur, consult a doctor immediately as severe cases may lead to renal dysfunction. Patients with liver function problems or a history of liver disease should consult a doctor before taking this medication and should undergo regular liver function tests. Patients with severe renal impairment, certain liver diseases, or muscle disorders should not use this medication. Patients with excessively low blood pressure or severe heart failure, acute myocardial infarction, or other cardiovascular issues need to take caution with this medication. This medication may increase blood potassium levels, so patients at risk of hyperkalemia should frequently check potassium levels through blood tests. When taken with other antihypertensives or lipid-lowering agents, there is a possibility of drug interactions, so it should be taken according to a doctor's guidance. Caution is needed when driving or operating machinery as dizziness or drowsiness may occur. If allergic reactions such as skin rash, difficulty breathing, or swelling of the face or lips occur while taking this medication, it should be discontinued immediately and medical personnel informed. This medication contains lactose, so patients with lactose intolerance should avoid it. Regular monitoring of blood pressure, liver function, renal function, blood lipids, and muscle condition is necessary while taking this medication.

Side effects

Increased ALT, Increased AST, Increased GGT, Edema, Orthostatic hypotension, Hyperkalemia, Facial edema, Strange sensations, Drug intolerance, Chest pain, Irritable bowel syndrome, Esophagitis, Dizziness, Somnolence, Neurodegenerative disorders, Positional dizziness, Migraine, Diabetes, Glucose load impairment, Depression, Bronchitis, Rhinitis, Cystitis, Onychomycosis, Soft tissue inflammation, Hepatic steatosis, Liver dysfunction, Hepatotoxicity, Acute hepatitis, Toxic hepatitis, Increased gamma-glutamyl transferase, Elevated blood cholesterol, Increased alkaline phosphatase, Irregular heart rate, Osteoarthritis, Osteoporosis, Musculoskeletal stiffness, Musculoskeletal discomfort, Muscle weakness, Cold sweat, Dermatitis, Skin burning sensation, Skin disorders, Alopecia, Oropharyngeal pain, Nasal congestion, Respiratory distress, Pelvic pain, Breast cysts, Eyelid drooping, Diabetic retinopathy, Ear discomfort, Renal dysfunction, Benign esophageal neoplasm, Thrombocytopenia, Anemia, Headache, Dizziness, Constipation, Nausea, Abdominal pain, Pancreatitis, Pruritus, Rash, Urticaria, Myalgia, Myopathy, Rhabdomyolysis, Asthenia, Petechiae, Erectile dysfunction, Cough, Dyspnea, Rhinitis, Hair loss, Hyperhidrosis, Purpura, Skin discoloration, Toxic epidermal necrolysis, Tension increase, Sensory loss, Sensory abnormalities, Peripheral neuropathy, Syncope, Taste disturbance, Tremor, Extrapyramidal disorders, Gynecomastia, Changes in bowel habits, Dry mouth, Dyspepsia, Gingival hypertrophy, Vomiting, Hyperglycemia, Thrombocytopenia, Depression, Insomnia, Anxiety, Syncope, Drowsiness, Visual disturbances, Vertigo, Bradycardia, Tachycardia, Hypotension, Vasculitis, Headache, Facial spasms, Sensory abnormalities, Paralysis, Hyperventilation, Pneumonia, Flushing, Loss of appetite, Arrhythmia, Decreased libido, Facial swelling, Conjunctivitis, Tinnitus, Chest pain, Chest discomfort, Generalized pain, Muscle cramps, Gout, Renal failure, Abnormal liver function tests, Hepatitis, Jaundice, Elevated liver enzymes, Anaphylaxis, Urticaria, Angioedema, Erythema multiforme, Increased creatine phosphokinase, Myopathy, Myalgia, Arthralgia, Low back pain, Muscle cramps, Myalgia, Increased blood creatinine, Increased blood uric acid, Increased blood creatine kinase, Hemoglobin decrease, Thrombocytopenia, Increased creatine kinase, Increased blood creatinine, Increased blood pressure, Increased blood urea, Urticaria, Hyperhidrosis, Rash, Pruritus, Upper respiratory infection, Conjunctival congestion, Renal failure, Abnormal liver function, Stevens-Johnson syndrome, Eosinophilia with systemic symptoms drug reaction syndrome, Drug eruption resembling psoriasis, Lupus-like syndrome, Muscle rupture, Immune-mediated necrotizing myopathy, Hematuria, Edema, Amnesia, Peripheral neuropathy, Oculobulbar weakness, Cholelithiasis, Cholecystitis, Skin mucosa syndrome, Toxic epidermal necrolysis, Erythema multiforme, Drug-induced hepatic damage, Tremor, Epigastric pain, Gastritis, Epigastric discomfort, Belching, Gastrointestinal disturbance, Gastroesophageal reflux disease, Tongue disorders, Congestive heart failure, Myocardial ischemia, Palpitations, Sputum, Rhinorrhea, Limb pain, Gynecomastia, Sexual dysfunction, Thrombocytopenia, Jaundice, Hepatitis, Elevated transaminases, Severe muscle weakness, Oculobulbar weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, and it is safe to store at room temperature between 1 degree and 30 degrees Celsius. Proper storage helps maintain the medication's efficacy and prevent degradation.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.